AllergyTalk

AllergyTalk Episode 59 - Can a Nasal Spray Prevent COVID?

Welcome to another episode of Allergy Talk, a roundup of the latest in the field of Allergy and Immunology by the American College of Allergy, Asthma, and Immunology. For today’s episode we will be reviewing articles from Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
Today we joined by Dr. Shyam Joshi, an associate professor and Section Chief at Oregon Health & Science University and Associate Editor of Allergy Watch! We will be reviewing the November-December 2025 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.To read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch. Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
Articles Reviewed:
Food-Induced Anaphylaxis: Data From the European Anaphylaxis Registry
Introduction of allergenic foods after treatment with omalizumab
Azelastine Nasal Spray for Prevention of SARS-CoV-2 Infections: A Phase 2 Randomized Clinical Trial.
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

AllergyTalk Episode 58: Is Zileuton the Next Treatment for Food Allergy?

Today we joined by Dr. Shyam Joshi, an associate professor and Section Chief at Oregon Health & Science University and Associate Editor of Allergy Watch! We will be reviewing the November-December 2025 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
And for those currently listening to the audio version, we are now releasing a video versions of AllergyTalk! Please visit the ACAAI YouTube channel at https://www.youtube.com/@allergists
To read archived issues of AllergyWatch, head over to http://college.acaai.org/publications/allergywatch
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
Articles Reviewed:
Paging ChatGPT: Potential and Limitations: Can ChatGPT provide parent education for oral immunotherapy? 
2024 Consensus Report: A New Consensus Definition for Anaphylaxis: Anaphylaxis definition, overview, and clinical support tool: 2024 consensus report-a GA(2)LEN project. 
Zileuton Prevents Food Allergen Induced Anaphylaxis in Mice: Cysteinyl leukotrienes stimulate gut absorption of food allergens to promote anaphylaxis in mice.
Please rate our podcast on Apple Podcasts or YouTube!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Food Allergy Frontlines: Clarifying Diagnosis, Advancing Treatment (3-part Miniseries, Part 3)

Part 3: Biologics in IgE-Mediated Food Allergy: Expanding the Toolbox This episode examines the growing role of biologic therapies like omalizumab in managing complex food allergies, reviewing trial data, mechanisms, and practical guidance for collaborative care.
Host Gerald Lee, MD, FACAAI, is joined by Brian P. Vickery, MD, Professor of Pediatrics, Marcus Professor of Pediatric Immunology, and Chief of the Division of Allergy/Immunology at Emory University and Children’s Healthcare of Atlanta, and Julie Wang, MD, FACAAI, Professor of Pediatrics in the Division of Allergy and Immunology at the Icahn School of Medicine at Mount Sinai.
For more information on this topic, please visit:
Anagnostou A, Abrams EM, Carver M, et al. Development and acceptability of a decision-aid for food allergy oral immunotherapy in children. Allergy. 2025;80(1):205-214. doi:10.1111/all.16332
Anagnostou A, Greenhawt M, Shaker M, Vickery BP, Wang J. Food allergy yardstick: Where does omalizumab fit?. Ann Allergy Asthma Immunol. 2025;134(1):110-121. doi:10.1016/j.anai.2024.07.034
Bartha I, Almulhem N, Santos AF. Feast for thought: A comprehensive review of food allergy 2021-2023. J Allergy Clin Immunol. 2024;153(3):576-594. doi:10.1016/j.jaci.2023.11.918
Dantzer J, Virkud Y, Wang J, et al. Introduction of allergenic foods after treatment with omalizumab. J Allergy Clin Immunol. 2025;156(2):394-405. doi:10.1016/j.jaci.2025.05.014
Wood RA, Togias A, Sicherer SH, et al. Omalizumab for the Treatment of Multiple Food Allergies. N Engl J Med. 2024;390(10):889-899. doi:10.1056/NEJMoa2312382
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion!
To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org!
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
This podcast miniseries is supported by Genentech.

Food Allergy Frontlines: Clarifying Diagnosis, Advancing Treatment (3-part Miniseries, Part 2)

Part 2: Immunotherapy for IgE-Mediated Food Allergy: OIT, SLIT & EPIT This episode explores FDA-approved and emerging immunotherapies for food allergy—OIT, SLIT, and EPIT—highlighting their indications, efficacy, safety, and role in shared decision-making.
Host Gerald Lee, MD, FACAAI, is joined by Edwin H. Kim, MD, FACAAI, Associate Professor of Pediatrics and Chief of the Division of Pediatric Allergy and Immunology at the University of North Carolina School of Medicine and Julie Wang, MD, FACAAI, Professor of Pediatrics in the Division of Allergy and Immunology at the Icahn School of Medicine at Mount Sinai.
For more information on this topic, please visit:
Anagnostou A, Abrams EM, Carver M, et al. Development and acceptability of a decision-aid for food allergy oral immunotherapy in children. Allergy. 2025;80(1):205-214. doi:10.1111/all.16332
Anagnostou A, Greenhawt M, Shaker M, Vickery BP, Wang J. Food allergy yardstick: Where does omalizumab fit?. Ann Allergy Asthma Immunol. 2025;134(1):110-121. doi:10.1016/j.anai.2024.07.034
Bartha I, Almulhem N, Santos AF. Feast for thought: A comprehensive review of food allergy 2021-2023. J Allergy Clin Immunol. 2024;153(3):576-594. doi:10.1016/j.jaci.2023.11.918
Dantzer J, Virkud Y, Wang J, et al. Introduction of allergenic foods after treatment with omalizumab. J Allergy Clin Immunol. 2025;156(2):394-405. doi:10.1016/j.jaci.2025.05.014
Wood RA, Togias A, Sicherer SH, et al. Omalizumab for the Treatment of Multiple Food Allergies. N Engl J Med. 2024;390(10):889-899. doi:10.1056/NEJMoa2312382
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion!
To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org!
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
This podcast miniseries is supported by Genentech.

Food Allergy Frontlines: Clarifying Diagnosis, Advancing Treatment (3-part Miniseries, Part 1)

Part 1: Diagnosis, Prevention & Early Management This episode explores how to accurately diagnose and manage food allergies in primary care, covering testing indications, referral criteria, prevention strategies, and risk stratification.
Host Gerald Lee, MD, FACAAI, is joined by Brian P. Vickery, MD, Professor of Pediatrics, Marcus Professor of Pediatric Immunology, and Chief of the Division of Allergy/Immunology at Emory University and Children’s Healthcare of Atlanta, and Edwin H. Kim, MD, FACAAI, Associate Professor of Pediatrics and Chief of the Division of Pediatric Allergy and Immunology at the University of North Carolina School of Medicine.
For more information on this topic, please visit:
Anagnostou A, Abrams EM, Carver M, et al. Development and acceptability of a decision-aid for food allergy oral immunotherapy in children. Allergy. 2025;80(1):205-214. doi:10.1111/all.16332
Anagnostou A, Greenhawt M, Shaker M, Vickery BP, Wang J. Food allergy yardstick: Where does omalizumab fit?. Ann Allergy Asthma Immunol. 2025;134(1):110-121. doi:10.1016/j.anai.2024.07.034
Bartha I, Almulhem N, Santos AF. Feast for thought: A comprehensive review of food allergy 2021-2023. J Allergy Clin Immunol. 2024;153(3):576-594. doi:10.1016/j.jaci.2023.11.918
Dantzer J, Virkud Y, Wang J, et al. Introduction of allergenic foods after treatment with omalizumab. J Allergy Clin Immunol. 2025;156(2):394-405. doi:10.1016/j.jaci.2025.05.014
Wood RA, Togias A, Sicherer SH, et al. Omalizumab for the Treatment of Multiple Food Allergies. N Engl J Med. 2024;390(10):889-899. doi:10.1056/NEJMoa2312382
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion!
To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org!
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
This podcast miniseries is supported by Genentech.

AllergyTalk Episode 57 - What Is the Risk of Dementia With Tiotropium?

Dr. Timothy Chow, Assistant Professor at UT Southwestern and an Assistant Editor of AllergyWatch® and hosts Dr. Gerald Lee, MD, FACAAI and Dr. Stanley Fineman, MD, MBA reviewed the July/August 2025 issue of AllergyWatch®.
Articles Reviewed:
Prenatal indoor PM2.5 exposure is associated with worse maternal asthma health and lung function
Want to help your patients with food allergy anxiety? Do proximity challenges!
Tiotropium initiation and dementia risk in chronic obstructive pulmonary disease
Read archived issues of AllergyWatch®.
Earn CME credit for listening to this episode! Free for College members!
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org!
The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

AllergyTalk Episode 56 - What Is the Best Management of High Threshold Food Allergies?

Dr. Timothy Chow, Assistant Professor at UT Southwestern and an Assistant Editor of AllergyWatch® and hosts Dr. Gerald Lee, MD, FACAAI and Dr. Stanley Fineman, MD, MBA reviewed the July/August 2025 issue of AllergyWatch®.
Articles Reviewed:
Integrated phase 1 pharmacokinetics and pharmacodynamics of epinephrine administered through sublingual film, autoinjector, or manual injection
Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies
Peanut oral immunotherapy in children with high-threshold peanut allergy
Read archived issues of AllergyWatch®.
Earn CME credit for listening to this episode! Free for College members!
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org!
The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

AllergyTalk Episode 55 - What Are the Best Criteria to Identify MCAS?

Dr. Shyam Joshi, MD, Associate Professor and Section Chief at Oregon Health & Science University and Associate Editor of AllergyWatch® and hosts Dr. Gerald Lee, MD, FACAAI and Dr. Stanley Fineman, MD, MBA reviewed the May/June 2025 issue of AllergyWatch®.
Articles Reviewed:
Outcomes of intravenous immunoglobulin treatment of immunocompromised patients with viral respiratory infections
A 1-Year Weight Management Program for Difficult-to-Treat Asthma With Obesity: A Randomized Controlled Study
Clustering of clinical symptoms using large language models reveals low diagnostic specificity of proposed alternatives to consensus mast cell activation syndrome criteria
Read archived issues of AllergyWatch®.
Earn CME credit for listening to this episode! Free for College members!
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org!
Speaker Disclosures:
Gerald Lee, MD: No relevant financial relationships with ineligible companies to discloseStanley Fineman, MD: No relevant financial relationships with ineligible companies to discloseShyam Joshi, MD: Advisor: Novartis; Speaker: Novartis; Consultant: Merida Bioscience
The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

AllergyTalk Episode 54 - Why Do Infections Worsen Anaphylaxis?

Dr. Shyam Joshi, MD, Associate Professor and Section Chief at Oregon Health & Science University and Associate Editor of AllergyWatch® and hosts Dr. Gerald Lee, MD, FACAAI and and Dr. Stanley Fineman, MD, MBA reviewed the May/June 2025 issue of AllergyWatch®.
Articles Reviewed:
Association of Allergy Specialty Care and Asthma Outcomes for Medicaid-Enrolled Children
Race-Specific and Race-Neutral Equations for Lung Function and Asthma Diagnosis in Black Children
Anaphylactic degranulation by mast cells requires the mobilization of inflammasome components
Read archived issues of AllergyWatch®.
Earn CME credit for listening to this episode! Free for College members!
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org!
Speaker Disclosures: Gerald Lee, MD: No relevant financial relationships with ineligible companies to discloseStanley Fineman, MD: No relevant financial relationships with ineligible companies to discloseShyam Joshi, MD: Advisor: Novartis; Speaker: Novartis; Consultant: Merida Bioscience
The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

AllergyTalk Episode 53 - Does Primary Care and Dermatology Follow Peanut Introduction Guidelines?

Dr. Sarah Spriet, DO, Staff Allergist and Clinical Immunologist at Alexander T. Augusta Military Medical Center in Northern Virginia. She is also a Core Faculty member for the National Capital Consortium Allergy-Immunology fellowship training program and an assistant editor of AllergyWatch® and hosts Dr. Gerald Lee, MD, FACAAI and Dr. Stanley Fineman, MD, MBA reviewed the January/February 2025 issue of AllergyWatch®.
Articles Reviewed:
Persistent cat ownership and asthma in a longitudinal study of Puerto Rican youth
The SQ tree sublingual immunotherapy tablet is effective and well tolerated in children – A pivotal phase III trial
Awareness and application of United States food allergy prevention guidelines among pediatricians and other clinicians
Read archived issues of AllergyWatch®.
Earn CME credit for listening to this episode! Free for College members!
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org!
Speaker Disclosures:Gerald Lee, MD: No relevant financial relationships with ineligible companies to discloseStanley Fineman, MD: No relevant financial relationships with ineligible companies to discloseSarah Spriet, DO: No relevant financial relationships with ineligible companies to disclose
The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.